Solifenacin is a competitive muscarinic antagonist that acts as an antimuscarinic agent. It is prescribed primarily to treat overactive bladder by reducing involuntary bladder contractions. The drug binds to muscarinic receptors in the detrusor muscle preventing acetylcholine mediated stimulation. This blockade decreases detrusor contractility and increases bladder capacity during filling. Pharmacodynamically the inhibition of cholinergic signaling leads to relaxation of the urinary tract smooth muscle. The medication is absorbed orally with a bioavailability that allows central and peripheral receptor interaction. Its long half-life supports sustained therapeutic effect over daily dosing.

Solifenacin is a medication classified as a muscarinic receptor antagonist used primarily to treat overactive bladder symptoms. It is formulated as an oral tablet that works by selectively blocking the activity of certain cholinergic receptors in the urinary tract. By inhibiting these receptors the drug reduces abnormal involuntary contractions of the detrusor muscle leading to improved bladder control. The therapeutic role of Solifenacin centers on alleviating urgency incontinence frequency and nocturia associated with overactive bladder syndrome. Pharmacologically the compound demonstrates high affinity for m3 muscarinic receptors which are predominantly responsible for mediating parasympathetic signaling in the bladder wall. This selective binding minimizes interaction with other receptor subtypes thereby reducing the likelihood of systemic side effects unrelated to the intended therapeutic outcome. Upon absorption Solifenacin undergoes hepatic metabolism producing active metabolites that maintain receptor antagonism throughout the dosing interval. The sustained blockade of m3 receptors results in decreased calcium mediated smooth muscle contraction and thus a direct relaxation of the urinary bladder detrusor muscle.

Headache is frequently reported among patients taking certain medications. Nausea can occur as a gastrointestinal reaction. Fatigue often appears as a sign of physiological adaptation. Dizziness may result from changes in blood pressure. Dry mouth is commonly noted during treatment. Mild skin rash appears in some cases. Blurred vision can develop temporarily. These effects usually diminish as the body adapts.

The most common side effects reported in clinical studies include headache fatigue and mild nausea. These reactions are typically mild and tend to resolve without intervention. Headache often appears early in the treatment course and may persist for a short duration. Fatigue frequently manifests as a feeling of low energy that diminishes over time. Mild nausea is characterized by a temporary upset in the gastrointestinal tract. Other frequently observed effects involve temporary muscle aches and occasional dizziness. These symptoms are generally self limiting and do not require medical treatment. Monitoring patients during the initial phase helps ensure that any adverse events remain within expected limits.